Background: Ingenol mebutate (IM), a novel agent for field therapy of actinic keratosis (AK), has a drawback of inducing local skin reactions (LSRs), which may cause discomfort in patients. To reduce the LSRs, we tried the application of IM in low amounts.
Objective: The purpose of this study was to review Korean patients with AK being treated with IM and evaluate the LSRs and therapeutic outcomes of low amounts of IM.
Methods: We retrospectively reviewed 47 patients with AK on the face. A total of 20 and 27 patients were treated by applying recommended amount of 18.8 mg/cm and the lower amount of 10 mg/cm, respectively.
Results: The mean composite LSR score for the low amount group (LAG; 12.18±3.29) was significantly lower than that for the recommended amount group (RAG; 15.45±2.70) (<0.01, independent sample -test). The 2-month clearance rate calculated by the number of AKs before and after treatment in each patient was significantly higher for RAG (88.16%), compared with 75.56% for LAG (<0.001).
Conclusion: Low amount of IM for the treatment of facial AK significantly reduced LSRs in Korean patients. Minimizing LSRs may allow for a secondary targeting treatment of IM for the residual lesions, depending on initial treatment outcomes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384689 | PMC |
| http://dx.doi.org/10.2147/CCID.S129072 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ingenol-3-Angelate Enhances the B Cell Inhibitory Potential of Mesenchymal Stem Cells, Leading to Marked Alleviation of Lupus Symptoms in MRL. Mice.
Int J Mol Sci
November 2024
College of Pharmacy, Chungbuk National University, Chungbuk 28160, Republic of Korea.
Article Synopsis
- Systemic lupus erythematosus (SLE) is a chronic autoimmune disease where hyper-activated B cells produce autoantibodies, causing symptoms.
- Research found that naïve mesenchymal stem cells (MSCs) inhibit T cell activity but not B cell IgM production, leading to a study on how to enhance MSC function.
- Treatment with ingenol-3-angelate (I3A) primes MSCs to inhibit B cells through the secretion of TGF-β1, showing improved effectiveness in alleviating SLE symptoms in mice.
International time trends and differences in topical actinic keratosis therapy utilization.
JAAD Int
September 2024
Department of Medicine, Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada.
Background: Actinic Keratoses (AK) are precancerous lesions that can lead to Squamous Cell Carcinoma. International differences in the utilization of topical medications to treat AK are not well described.
Objectives: To describe international differences in topical AK medication utilization, including associations of countries' economic status with AK medication utilization.
Ingenol mebutate-associated immune thrombocytopenic purpura.
JAAD Case Rep
April 2024
Dermatology Solutions, Grapevine, Texas.
Field Cancerization Therapies for the Management of Actinic Keratosis: An Updated Review.
Am J Clin Dermatol
May 2024
Department of Dermatology, University of Illinois College of Medicine, 808 S. Wood St., Suite 380, Chicago, IL, 60612, USA.
Field cancerization theory highlights that the skin surrounding actinic keratoses (AK) is also at increased risk for possible malignant transformation; thus, field-directed treatments may both reduce the risk of AK recurrence and potentially reduce the risk of development of cutaneous squamous cell carcinoma (cSCC). Photodynamic therapy (PDT) with either aminolevulinic acid (ALA) or methylaminolevulinate (MAL), as well as topical treatments such as 5-fluorouracil (5-FU), diclofenac gel, piroxicam, imiquimod, and ingenol mebutate, have all shown higher efficacy than vehicle treatments. PDT is widely recognized for its high efficacy; however, concerns for associated pain have driven new studies to begin using alternative illumination and pretreatment techniques, including lasers.
View Article and Find Full Text PDFIdentification and validation of a glycolysis-related taxonomy for improving outcomes in glioma.
CNS Neurosci Ther
February 2024
Department of Urology, Shengjing Hospital of China Medical University, Shenyang, China.
Background: Reprogramming of glucose metabolism is a prominent abnormal energy metabolism in glioma. However, the efficacy of treatments targeting glycolysis varies among patients. The present study aimed to classify distinct glycolysis subtypes (GS) of glioma, which may help to improve the therapy response.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!